Important note: Information in this article was accurate in January 2009. The state of the art may have changed since the publication date.
EMEA approves once-daily darunavir/ritonavir (800mg/100mg) for treatment-naïve patients in Europe
HIV Treat Bull - 2009 Jan-Feb;10(1/2): 20
On 3 February 2009, the European Commission approved once-daily dosing of 800 mg darunavir (Prezista),, with low-dose ritonavir as part of combination therapy in treatment-naïve adults.
The approval is based on 48-week analyses from the Artemis Study, an open label phase III trial in antiretroviral treatment- naïve HIV-1-infected adults which compared darunavir/r vs. lopinavir/r in combination with other antiretrovirals. The results showed that darunavir was non-inferior to the lopinavir/r, (84% vs. 78% achieved viral load <50 copies/mL compared to lopinavir/r ). The common adverse drug reactions reported of at least moderate intensity (=Grade 2) in the darunavir/r arm were hypertriglyceridaemia, hypercholesterolaemia, headache, diarrhoea, nausea, and increased alanine aminotransferase.
Darunavir was given conditional marketing authorisation by the European Commission in February 2007, and received full marketing authorisation in December 2008.
The recommended dosing for treatment-naïve adult patients is 800 mg (two 400 mg tablets) taken with 100 mg ritonavir once daily.
For treatment-experienced adult patients, the dosing for darunavir remains 600 mg taken with 100 mg ritonavir twice daily. Darunavir must be taken with food and in combination with other ARVs. Darunavir is not recommended for use in patients with severe hepatic impairment.
Source: Tibotec Press Release ‘Once-daily darunavir/r for treatment-naïve adults with HIV-1 receives approval in the European Union as part of combination therapy’. (3 February 2009)
2009-02-10
IB2009-01-20
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.